Black Diamond Therapeutics, Inc. (BDTX) — SEC Filings
Black Diamond Therapeutics, Inc. (BDTX) — 30 SEC filings. Latest: 8-K (Dec 3, 2025). Includes 10 8-K, 6 10-Q, 4 SC 13G/A.
View Black Diamond Therapeutics, Inc. on SEC EDGAR
Overview
Black Diamond Therapeutics, Inc. (BDTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Black Diamond Therapeutics, Inc. (BDTX) reported a significant financial turnaround for the nine months ended September 30, 2025, achieving a net income of $37,483 thousand, a stark contrast to the net loss of $53,691 thousand in the same period of 2024. This improvement was primarily driven by $70,
Sentiment Summary
Across 30 filings, the sentiment breakdown is: 1 bearish, 28 neutral, 1 mixed. The dominant filing sentiment for Black Diamond Therapeutics, Inc. is neutral.
Filing Type Overview
Black Diamond Therapeutics, Inc. (BDTX) has filed 10 8-K, 6 10-Q, 2 DEF 14A, 1 10-K, 4 SC 13G/A, 4 SC 13G, 3 SC 13D/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (30)
Risk Profile
Risk Assessment: Of BDTX's 19 recent filings, 1 were flagged as high-risk, 12 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $70,000 |
| Net Income | $37,483 |
| EPS | $0.65 |
| Debt-to-Equity | 0.25 |
| Cash Position | $30,864 |
| Operating Margin | N/A |
| Total Assets | $157,733 |
| Total Debt | $31,581 |
Key Executives
- Dr. David Pesman
- Ms. Sarah E. Kelly
- Ali Behbahani
- Anthony A. Florence, Jr.
- Carmen Chang
- Forest Baskett
- Mohamad H. Makhzoumi
- Paul Walker
- Peter Kolchinsky
- Rajeev Shah
- Dr. David Epstein
Industry Context
Black Diamond Therapeutics operates in the highly competitive oncology drug development sector. The industry is characterized by significant R&D investment, long development cycles, and stringent regulatory hurdles. Companies often rely on strategic partnerships and licensing deals to advance their pipelines and manage financial risk.
Top Tags
financials (5) · corporate-governance (4) · 10-Q (4) · biotech (4) · Biotechnology (3) · Oncology (2) · Clinical Trials (2) · disclosure (2) · amendment (2) · venture-capital (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| License revenue | $70,000 | Generated for the nine months ended September 30, 2025, compared to $0 in 2024, driving profitability. |
| Net income | $37,483 | For the nine months ended September 30, 2025, a significant turnaround from a $53,691 thousand net loss in 2024. |
| Net loss | $8,498 | For the three months ended September 30, 2025, an improvement from $15,557 thousand loss in Q3 2024. |
| Research and development expenses | $27,262 | For the nine months ended September 30, 2025, a decrease from $39,015 thousand in 2024. |
| General and administrative expenses | $12,606 | For the nine months ended September 30, 2025, a decrease from $21,491 thousand in 2024. |
| Cash and cash equivalents | $30,864 | As of September 30, 2025, a decrease from $36,437 thousand at December 31, 2024. |
| Investments | $104,639 | As of September 30, 2025, an increase from $62,138 thousand at December 31, 2024. |
| Shares of common stock outstanding | 56,974,913 | As of October 30, 2025, indicating dilution or share-based compensation. |
| Revenue | $0 | No revenue for Q2 2025 and YTD 2025, indicating pre-commercial stage. |
| Net Loss (Q2 2025) | $35.2M | Increased 10.7% from $31.8M in Q2 2024, showing widening losses. |
| Net Loss (YTD 2025) | $70.5M | Increased 10.2% from $64.0M in YTD 2024, reflecting higher expenses. |
| R&D Expenses (Q2 2025) | $29.8M | Up from $26.5M in Q2 2024, demonstrating continued pipeline investment. |
| Cash and Cash Equivalents | $250.3M | Decreased from $310.5M at Dec 31, 2024, indicating significant cash burn. |
| Increase in Net Loss (Q2 YoY) | 10.7% | Percentage increase in net loss from Q2 2024 to Q2 2025. |
| Increase in Net Loss (YTD YoY) | 10.2% | Percentage increase in net loss from YTD 2024 to YTD 2025. |
Frequently Asked Questions
What are the latest SEC filings for Black Diamond Therapeutics, Inc. (BDTX)?
Black Diamond Therapeutics, Inc. has 30 recent SEC filings from Jan 2024 to Dec 2025, including 10 8-K, 6 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BDTX filings?
Across 30 filings, the sentiment breakdown is: 1 bearish, 28 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Black Diamond Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Black Diamond Therapeutics, Inc. (BDTX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Black Diamond Therapeutics, Inc.?
Key financial highlights from Black Diamond Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BDTX?
The investment thesis for BDTX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Black Diamond Therapeutics, Inc.?
Key executives identified across Black Diamond Therapeutics, Inc.'s filings include Dr. David Pesman, Ms. Sarah E. Kelly, Ali Behbahani, Anthony A. Florence, Jr., Carmen Chang and 6 others.
What are the main risk factors for Black Diamond Therapeutics, Inc. stock?
Of BDTX's 19 assessed filings, 1 were flagged high-risk, 12 medium-risk, and 6 low-risk.
What are recent predictions and forward guidance from Black Diamond Therapeutics, Inc.?
Forward guidance and predictions for Black Diamond Therapeutics, Inc. are extracted from SEC filings as they are enriched.